At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Systemic Pharmacokinetics Following Intravitreal Injections of Ranibizumab, Bevacizumab or Aflibercept in Patients With Neovascular Age-related Macular Degeneration
In Brief
A Phase 2 clinical trial evaluating Blood Sample Collection, Aflibercept, and 2 other interventions for Age-related Macular Degeneration and 2 related conditions. Completed, enrolled 56 participants.
Detailed Summary
Comparable data for bevacizumab and aflibercept are lacking, as are studies comparing the systemic levels of ranibizumab, bevacizumab, and aflibercept and their relative effects on circulating vascular endothelial growth factor. In the present prospective study, the investigators evaluated serum drug levels and plasma free vascular endothelial growth factor (VEGF) levels in patients with neovascular age-related macular degeneration following intravitreal injections of ranibizumab, bevacizumab and aflibercept.
Study Details
Timeline
Interventions
Subjects will have their blood drawn for analysis following their first and third injections of anti-VEGF.
an intravitreal injection of Aflibercept administered three times on a monthly basis.
an intravitreal injection of Bevacizumab administered three times on a monthly basis.
an intravitreal injection of Ranibizumab administered three times on a monthly basis.